Kurs & Likviditet
+0,10%
|
2,04 MNOK
Kursutveckling och likviditet under dagen för detta pressmeddelande
Kalender
2023-11-08 | Kvartalsrapport 2023-Q3 |
2023-08-09 | Kvartalsrapport 2023-Q2 |
2023-05-10 | Kvartalsrapport 2023-Q1 |
2023-05-04 | Ordinarie utdelning PHO 0.00 NOK |
2023-05-03 | Årsstämma 2023 |
2023-02-24 | Bokslutskommuniké 2022 |
2023-02-23 | Bokslutskommuniké 2022 |
2022-11-02 | Kvartalsrapport 2022-Q3 |
2022-08-10 | Kvartalsrapport 2022-Q2 |
2022-05-11 | Kvartalsrapport 2022-Q1 |
2022-04-29 | Ordinarie utdelning PHO 0.00 NOK |
2022-04-28 | Årsstämma 2022 |
2022-02-23 | Bokslutskommuniké 2021 |
2021-11-17 | Kvartalsrapport 2021-Q3 |
2021-08-11 | Kvartalsrapport 2021-Q2 |
2021-07-28 | Extra Bolagsstämma 2021 |
2021-05-21 | Ordinarie utdelning PHO 0.00 NOK |
2021-05-20 | Årsstämma 2021 |
2021-05-19 | Kvartalsrapport 2021-Q1 |
2021-03-03 | Bokslutskommuniké 2020 |
2020-11-10 | Kvartalsrapport 2020-Q3 |
2020-08-18 | Kvartalsrapport 2020-Q2 |
2020-06-11 | Ordinarie utdelning PHO 0.00 NOK |
2020-06-10 | Årsstämma 2020 |
2020-05-07 | Kvartalsrapport 2020-Q1 |
2020-02-27 | Bokslutskommuniké 2019 |
2019-11-07 | Kvartalsrapport 2019-Q3 |
2019-08-07 | Kvartalsrapport 2019-Q2 |
2019-06-19 | Extra Bolagsstämma 2019 |
2019-05-14 | Kvartalsrapport 2019-Q1 |
2019-05-10 | Ordinarie utdelning PHO 0.00 NOK |
2019-05-09 | Årsstämma 2019 |
2019-02-27 | Bokslutskommuniké 2018 |
2018-11-08 | Kvartalsrapport 2018-Q3 |
2018-08-08 | Kvartalsrapport 2018-Q2 |
2018-05-23 | Kvartalsrapport 2018-Q1 |
2018-05-11 | Ordinarie utdelning PHO 0.00 NOK |
2018-05-09 | Årsstämma 2018 |
2018-02-27 | Bokslutskommuniké 2017 |
2017-11-08 | Kvartalsrapport 2017-Q3 |
2017-08-23 | Kvartalsrapport 2017-Q2 |
2017-05-23 | Kvartalsrapport 2017-Q1 |
2017-04-28 | Ordinarie utdelning PHO 0.00 NOK |
2017-04-27 | Årsstämma 2017 |
2017-02-15 | Bokslutskommuniké 2016 |
2016-11-15 | Kvartalsrapport 2016-Q3 |
2016-08-23 | Kvartalsrapport 2016-Q2 |
2016-05-10 | Kvartalsrapport 2016-Q1 |
2016-04-29 | Ordinarie utdelning PHO 0.00 NOK |
2016-04-28 | Årsstämma 2016 |
2016-02-11 | Bokslutskommuniké 2015 |
2015-10-29 | Kvartalsrapport 2015-Q3 |
2015-08-13 | Kvartalsrapport 2015-Q2 |
2015-05-06 | Kvartalsrapport 2015-Q1 |
2015-05-02 | Ordinarie utdelning PHO 0.00 NOK |
2015-04-30 | Årsstämma 2015 |
2015-02-12 | Bokslutskommuniké 2014 |
2014-11-06 | Kvartalsrapport 2014-Q3 |
2014-08-26 | Kvartalsrapport 2014-Q2 |
2014-05-28 | Ordinarie utdelning PHO 0.00 NOK |
2014-05-27 | Årsstämma 2014 |
2014-05-07 | Kvartalsrapport 2014-Q1 |
2014-02-27 | Bokslutskommuniké 2013 |
2013-10-23 | Kvartalsrapport 2013-Q3 |
2013-08-22 | Kvartalsrapport 2013-Q2 |
2013-05-23 | Ordinarie utdelning |
2013-05-22 | Årsstämma 2013 |
2013-04-25 | Kvartalsrapport 2013-Q1 |
2013-02-28 | Bokslutskommuniké 2012 |
2012-10-26 | Kvartalsrapport 2012-Q3 |
2012-08-24 | Kvartalsrapport 2012-Q2 |
2012-05-10 | Årsstämma 2012 |
2012-04-26 | Kvartalsrapport 2012-Q1 |
2012-02-16 | Bokslutskommuniké 2011 |
2011-10-26 | Kvartalsrapport 2011-Q3 |
2011-08-18 | Kvartalsrapport 2011-Q2 |
2011-04-27 | Kvartalsrapport 2011-Q1 |
2011-04-27 | Årsstämma 2011 |
2011-02-17 | Bokslutskommuniké 2010 |
2010-10-27 | Kvartalsrapport 2010-Q3 |
2010-08-19 | Kvartalsrapport 2010-Q2 |
2010-04-28 | Kvartalsrapport 2010-Q1 |
2010-02-19 | Bokslutskommuniké 2009 |
2009-11-26 | Bonusutdelning |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Medicinteknik |
2022-12-05 07:30:22
Press release - Oslo, Norway, December 5th, 2022: Photocure ASA, The Bladder
Cancer Company, announces that new evidence was presented at the 22[nd] Annual
Society of Urologic Oncology (SUO) Meeting demonstrating that Blue Light
Cystoscopy (BLC[®]) decreases the risk and prolongs time to recurrence based on
Real World Evidence from the U.S. multi-institutional Blue Light Cystoscopy with
Cysview[®] Registry database.
This large, prospective, longitudinal, multisite registry collects data on
NMIBC* patients who have undergone transurethral resection of bladder tumor
(TURBT) using Blue Light as an adjunct to white light cystoscopy (WLC). The new
data represent an interim analysis of the study, which is projected to enroll
4,400 patients in total. In this study, all registry patients analyzed (n=2055)
received Blue Light. They were directly compared to a historical White-Light
(WL)-only control group (n=261) of similar age, stage, grade, and clinical
management (i.e., intravesical therapy).
Kaplan-Meier curves demonstrate recurrence-free survival (RFS) for BLC patients
compared to a WL-only arm with a mean follow up of 27.4 months for BLC and 53
months for the historical WL control arm. The overall risk of recurrence was
significantly lower following BLC compared to WLC alone (Hazard Ratio (HR) 0.33